ERBB2 and neoplasm: Finally, we combine protein array and single-cell CycIF multiplex methods to identify a previously unrecognized PEAK1-INHBA-antiapoptotic stromal-tumor cell signaling axis that may be leveraged to abrogate therapeutic resistance in HER2-positive breast cancer and improve patient outcomes.